What the 2026 FDA hormone-therapy label change means

What actually changed in 2026?

For about two decades every estrogen product for menopause carried the FDA's strongest safety notice, a boxed warning, headed "WARNING: CARDIOVASCULAR DISORDERS, PROBABLE DEMENTIA, BREAST CANCER, and ENDOMETRIAL CANCER." On February 12, 2026 the FDA approved new labels for the first six of these products that drop three of those four risks from the boxed warning: cardiovascular disease, breast cancer, and probable dementia.

Those three risks are not erased. They move out of the boxed warning and into the ordinary Warnings and Precautions section, now written with age-specific context instead of a single class-wide alarm. The endometrial-cancer warning is the one that stays boxed, on systemic estrogen-alone products for women with a uterus.

• Removed from the boxed warning: cardiovascular disease, breast cancer, probable dementia.
• Kept in the boxed warning: endometrial cancer, on systemic estrogen-alone products for women with a uterus.
• New framing: benefits favor starting within 10 years of menopause or before age 60.
• First batch: 6 products finalized February 12, 2026; 29 companies have submitted proposed labeling changes, so more will follow.

Why was the 2002 warning there in the first place?

The warnings trace back to the Women's Health Initiative (WHI), a large federal study launched in 1991. On July 9, 2002 its data-safety board halted the estrogen-plus-progestin arm early, reporting that the combination raised the risk of stroke, blood clots, heart events, and invasive breast cancer for the women enrolled. The finding made headlines worldwide.

In 2003 the FDA responded with its boxed warning on menopausal estrogen products. A companion arm of the study, the WHI Memory Study, later linked hormone therapy to a higher rate of probable dementia in women aged 65 and older, and that risk was added too. The effect on practice was immediate and lasting: US hormone-therapy use fell from roughly 27% of postmenopausal women in 1999 to about 5% by 2020, per Harvard Health.

What is the timing hypothesis, and why did it change the science?

The catch with the 2002 result is who was studied. WHI enrolled women aged 50 to 79, but the average participant was in her early 60s and many were more than a decade past menopause, often with existing cardiovascular risk. Starting hormones in that group is a different question from starting them around the time menopause begins.

When researchers re-analyzed the data by age and by how long since menopause, a pattern held up: women who begin hormone therapy within about 10 years of menopause, or before age 60, tend to see the benefits (bone protection, symptom relief, and in several analyses lower all-cause mortality) outweigh the risks. This is the timing hypothesis, sometimes called the window of opportunity. Formulations also changed since 2002, with transdermal estrogen and micronized progesterone now common, which carry a different risk profile from the oral conjugated-estrogen-plus-synthetic-progestin combination WHI tested.

What happened at the July 17, 2025 FDA expert panel?

On July 17, 2025 the FDA convened a 12-member expert panel, chaired under Commissioner Marty Makary, to reweigh the evidence on menopausal hormone therapy. The panel included clinicians and researchers such as JoAnn Manson of Brigham and Women's Hospital, cardiologist Howard Hodis, neuroscientist Roberta Diaz Brinton, and gynecologist Mary Jane Minkin.

Several panelists argued that applying one boxed warning across every product, including low-dose vaginal estrogen that is barely absorbed, overstated the risk and scared women away from effective treatment. The panel stressed the differences between systemic and local estrogen, between estrogen-alone and estrogen-plus-progestogen, and the importance of formulation, dose, route, and timing. Its report was later published in the journal Menopause.

What did the FDA announce on November 10, 2025?

After the panel, a 60-day public comment period, and an independent literature review, the FDA and HHS announced on November 10, 2025 that they would remove the boxed warnings on cardiovascular disease, breast cancer, and probable dementia from all estrogen-containing menopause products. Commissioner Makary framed the old warnings as based on outdated science that had discouraged women from a treatment many could benefit from.

The announcement was a decision, not the finished labels. It set the direction and asked manufacturers to submit updated labeling, with the actual product-by-product changes to roll out over the following months. It also kept the endometrial-cancer warning on systemic estrogen-alone therapy in place.

Which six products got new labels on February 12, 2026?

The February 12, 2026 approvals are the first concrete labels, chosen so that all four categories of menopausal hormone therapy are represented. Twenty-nine companies have submitted proposed changes at the FDA's request, so this is the first batch, not the last.

• Bijuva (estradiol and progesterone) - systemic combination therapy.
• Divigel (estradiol gel) - systemic estrogen-alone therapy.
• Cenestin (synthetic conjugated estrogens, A) - systemic estrogen-alone therapy.
• Enjuvia (synthetic conjugated estrogens, B) - systemic estrogen-alone therapy.
• Prometrium (micronized progesterone) - systemic progestogen-alone therapy, taken with estrogen by women with a uterus.
• Estring (estradiol vaginal ring) - topical vaginal estrogen therapy.

What do the new labels say vs the old ones?

The clearest way to see the change is side by side. The old boxed warning applied the same four-risk alarm to every product as a class. The 2026 labels keep only endometrial cancer boxed, move the other three risks into the standard warnings text, and add age-specific framing about when hormone therapy is most favorable.

What does this mean for a woman deciding today?

Practically, the change lowers the wall of fear that a boxed warning puts between a patient and a prescription. If you are in your 40s or 50s, within roughly 10 years of menopause, and weighing hormone therapy for hot flashes, sleep, mood, or bone protection, the label change reflects what many menopause specialists have said for years: for that group the benefits often outweigh the risks.

It does not make hormone therapy right for everyone or risk-free. The decision still depends on your age, how long since menopause, your personal and family history (especially of breast cancer, blood clots, stroke, or heart disease), whether you have a uterus, and which formulation and dose you use. The label change is a reason to have the conversation with an informed clinician, not a reason to skip it.

What did NOT change?

Several things stayed exactly the same, and it is worth being precise about them so the headlines do not oversell the news.

• The endometrial-cancer boxed warning remains on systemic estrogen-alone products for women with a uterus, which is why progesterone is still added to protect the uterine lining.
• The underlying risks were reclassified, not deleted. Cardiovascular, breast-cancer, and clot risks still appear in the labels' warnings and precautions, now with age and timing context.
• Hormone therapy still requires a prescription and individualized counseling; it is not newly available over the counter.
• As of this update, six products carry finalized labels. Others still show the old boxed warning until their own updates are approved.
• Nothing here is a personal recommendation to start, stop, or change hormone therapy. That is a decision for you and your clinician.